Litcius/Paper detail

SARS-CoV-2 Variant Exposures Elicit Antibody Responses With Differential Cross-Neutralization of Established and Emerging Strains Including Delta and Omicron

Matthew T. Laurie, Jamin Liu, Sara Sunshine, James Peng, Douglas Black, Anthea Mitchell, Sabrina A Mann, Genay Pilarowski, Kelsey C. Zorn, Luis Rubio, Sara Bravo, Carina Marquez, Joseph J. Sabatino, Kristen Mittl, Maya Petersen, Diane V. Havlir, Joseph L. DeRisi

2022The Journal of Infectious Diseases47 citationsDOIOpen Access PDF

Abstract

The wide spectrum of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants with phenotypes impacting transmission and antibody sensitivity necessitates investigation of immune responses to different spike protein versions. Here, we compare neutralization of variants of concern, including B.1.617.2 (delta) and B.1.1.529 (omicron), in sera from individuals exposed to variant infection, vaccination, or both. We demonstrate that neutralizing antibody responses are strongest against variants sharing certain spike mutations with the immunizing exposure, and exposure to multiple spike variants increases breadth of variant cross-neutralization. These findings contribute to understanding relationships between exposures and antibody responses and may inform booster vaccination strategies.

Topics & Concepts

NeutralizationAntibodyVirologyNeutralizing antibodyBiologySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)VaccinationImmunologyPhenotypeImmune systemCoronavirus disease 2019 (COVID-19)MedicineGeneGeneticsInfectious disease (medical specialty)DiseasePathologySARS-CoV-2 and COVID-19 ResearchAnimal Virus Infections Studiesvaccines and immunoinformatics approaches
SARS-CoV-2 Variant Exposures Elicit Antibody Responses With Differential Cross-Neutralization of Established and Emerging Strains Including Delta and Omicron | Litcius